Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
1997 3
1998 2
2000 6
2001 7
2002 19
2003 20
2004 10
2005 7
2006 13
2007 12
2008 15
2009 16
2010 21
2011 17
2012 6
2013 11
2014 13
2015 10
2016 3
2017 2
2018 1
2019 3
2020 8
2021 6
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 12384408

210 results

Results by year

Filters applied: . Clear all
Page 1
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, García-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S; Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation. Pérez-Simón JA, et al. Blood. 2002 Nov 1;100(9):3121-7. doi: 10.1182/blood-2002-03-0701. Blood. 2002. PMID: 12384408 Free article.
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, Clark FJ, Hunt L, Yin J, Fuller S, Vandenberghe E, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter A, Chopra R, Davies A, Towlson K, Williams CD. Marks DI, et al. Blood. 2002 Nov 1;100(9):3108-14. doi: 10.1182/blood-2002-02-0506. Blood. 2002. PMID: 12384406 Free article.
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S. Kottaridis PD, et al. Blood. 2000 Oct 1;96(7):2419-25. Blood. 2000. PMID: 11001893 Free article. Clinical Trial.
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Coleman M, Feldman EJ, Silver RT. Shore T, et al. Biol Blood Marrow Transplant. 2006 Aug;12(8):868-75. doi: 10.1016/j.bbmt.2006.05.006. Biol Blood Marrow Transplant. 2006. PMID: 16864057 Free article. Clinical Trial.
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, Ruiz de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, MacKinnon S. Kottaridis PD, et al. Cytotherapy. 2001;3(3):197-201. doi: 10.1080/146532401753174025. Cytotherapy. 2001. PMID: 12171726 Clinical Trial.
Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
Patel K, Parmar S, Shah S, Shore T, Gergis U, Mayer S, van Besien K. Patel K, et al. Biol Blood Marrow Transplant. 2016 Mar;22(3):456-61. doi: 10.1016/j.bbmt.2015.10.022. Epub 2015 Oct 31. Biol Blood Marrow Transplant. 2016. PMID: 26524732 Free PMC article.
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Lush RJ, Haynes AP, Byrne J, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, Craddock CF, Lui Yin JA, Garg M, Prentice HG, Potter MN, Russell NH. Lush RJ, et al. Cytotherapy. 2001;3(3):203-10. doi: 10.1080/146532401753174034. Cytotherapy. 2001. PMID: 12171727 Clinical Trial.
210 results